Key Drivers
- High gross margin
- Weak full-year profitability
- Excessive leverage
AIAI Summary
iRhythm's business has shifted from growth-at-all-costs to a viable growth-plus-profitability story—evidence of positive quarterly GAAP income and first annual free cash flow makes the equity a conditional buy, but investors should require visible execution of >20% revenue growth, sustained ~70% gross margins, and a credible plan to meaningfully cut its ~$731M debt (or clear key FDA/litigation milestones) before adding exposure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Weak full-year profitability
- •Excessive leverage
IRTC combines very strong gross margin and short-term liquidity with improving quarterly cash profitability but suffers from heavy operating losses, very high leverage and rich valuation multiples.
Price Behavior
Key Price Behavior Insights:
- •Strong downtrend
- •Trading below MA
- •Support at $113
Over the last month the stock plunged ~22–23% from $150.96 to $116.28, trading below its ~ $126 last-month moving average (now near-term resistance) with nearest support at $113, signaling bearish momentum where a break under $113 could open further downside amid elevated short-term volatility.
Sharp ~22–23% drop from $150.96 to $116.28 over last month, indicating elevated short-term volatility
Sentiment & News
Key News Insights:
- •Board appointment
- •Institutional shift
- •Insider sale
iRhythm strengthened its board with Jason Patten while significant insider and institutional trading (Artisan sell-down, Cinctive new stake, CEO sale) and media comparisons kept investor focus on the stock.
Board reinforcement may stabilize governance perception but active insider and institutional flows suggest near-term share movement and continued analyst scrutiny
Similar Companies in Healthcare
Other companies in the same sector with AI ratings